NATCO Pharma approves stake increase in Adcock Ingram to 49% for ₹1,069 crore
Natco Pharma · Pharmaceuticals & Biotechnology
Key highlights
- NATCO Pharma to acquire 19,618,825 shares of Adcock Ingram Holdings Proprietary Limited at ZAR 92.50 per share
- Investment valued at approximately ZAR 1.8 billion (₹1,069 crores), increasing stake from 35.75% to 49%
- Acquisition expected to complete before end of July 2026, via cash consideration subject to regulatory approvals
Why it's rated notable: amount is ₹500 crore or more
Original filing
Board Meeting Outcome for Outcome Of Board Meeting
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Natco Pharma
- Fundraise / allotmentNotableNatco Pharma allots 1,70,58,082 equity shares in Rights Issue at ₹750 each
- Board / shareholder meeting outcomeMajor developmentNatco Pharma Limited announces results of 43rd AGM held on 30 September 2026
- Fundraise / allotmentNotableNATCO Pharma Limited files Letter of Offer for Rights Issue closing Oct 22, 2026
- Fundraise / allotmentNotableNatco Pharma board approves rights issue of up to ₹12,79,35,61,500
- Fundraise / allotmentNotableNatco Pharma approves rights issue of up to ₹12,79,35,61,500 via 1,70,58,082 shares
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.